| 摘要: |
| 目的 探讨XELOX方案一线化疗加卡培他滨维持治疗晚期胃癌的有效性与安全性。方法 32例胃癌患者采用XELOX方案进行初始化疗；6个周期后,疗效评价无疾病进展的患者进行后续的卡培他滨维持化疗,持续到疾病进展或不能耐受毒副反应为止。结果 一线化疗后有效率(RR)为46.9%(15/32)；26例患者进入卡培他滨维持化疗,疗效再评价,RR为26.9% (7/26)。全组中位PFS为8.9个月,1 年生存率为56.2%(18/32),2年生存率为31.2% (10/32)。主要的不良反应有恶心、呕吐、腹泻、骨髓抑制、神经毒性、手足综合征等,可耐受。 结论 对晚期胃癌患者采用XELOX方案一线化疗继之卡培他滨维持治疗,近期有效率高,安全性好,且能带来一定程度的生存获益。 |
| 关键词: 胃肿瘤 化疗 卡培他滨 奥沙利铂 |
| DOI：10.3724/SP.J.1008.2015.00346 |
| 投稿时间：2014-10-18修订日期：2014-12-19 |
| 基金项目: |
|
| First line XELOX chemotherapy combined with subsequent capecitabine maintenance chemotherapy for patients with advanced gastric cancer: a clinical analysis of effectiveness |
| YANG Jing1,2,WU Mian-hua1,ZHANG Qi2,WANG Xiang3* |
(1. First Clinical College, Nanjing Chinese Medicine University, Nanjing 210042, Jiangsu, China;
2. Department of Medical Oncology, Xuzhou Chinese Medicine Hospital, Xuzhou 221003, Jiangsu, China;
3. Department of Medical Oncology, Xuzhou Central Hospital, Xuzhou 221009, Jiangsu, China
*Corresponding author) |
| Abstract: |
| Objective To investigate the eurative effect and safety of oxaliplatin plus capecitabine with subsequent capecitabine maintenance chemotherapy for patients with advanced gastric cancer. Methods A total of 32 patients were enrolled into this study, they received first line oxaliplatin plus capecitabine (XELOX) chemotherapy. Patients without tumor progression were assigned to the group with capecitabine maintenance chemotherapy. Results: The response rate (RR) of first-line chemotherapy was 46.9% (15/32); 26 patients entered the capecitabine maintenance chemotherapy group, RR was 26.9% (7/26). The median PFS of whole group was 8.9 months, 1 and 2 year survival rate were 56.2% (18/32) and 31.2% (10/32), respectively. The main adverse reactions were nausea, vomiting, diarrhea, bone marrow suppression, neurotoxicity and hand foot syndrome, which can be tolerated. Conclusion XELOX regimen chemotherapy followed by capecitabine maintenance therapy for advanced gastric cancer patients is effective and safe, while bring a certain degree of survival benefit. |
| Key words: stomach neoplasms drug therapy capecitabine oxaliplatin |
